Raffaele Califano
Wilmslow Road
Manchester, ENG, United Kingdom
Manchester, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 110 publications
Improving dermatological adverse events from amivantamab plus lazertinib: lessons from the COCOON trial.
Journal: Journal of thoracic disease
Published: March 12, 2026
From Simple Scores to Intelligent Systems: Encouraging the Development, Validation and Adoption of Robust Prognostic Tools in Small Cell Lung Cancer.
Journal: Technology in cancer research & treatment
Published: January 23, 2026
Antibody-Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: January 14, 2026
Overall survival according to timing of immune checkpoint inhibitors administration in patients with advanced cancer: results from a large single-centre cohort analysis.
Journal: British journal of cancer
Published: November 07, 2025
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.
Journal: The New England journal of medicine
Published: September 09, 2025
Response to letter Re: "Consolidation thoracic radiotherapy after chemoimmunotherapy in ES-SCLC: A multicentric retrospective analysis".
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 02, 2025
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 22, 2025
Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib.
Journal: Clinical lung cancer
Published: August 19, 2025
Response to Letter to the Editor on "Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy".
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 27, 2025
NY-ESO-1 targeting in non-small cell lung cancer: promise and challenges of letetresgene autoleucel.
NY-ESO-1 targeting in non-small cell lung cancer: promise and challenges of letetresgene autoleucel.
Journal: Translational lung cancer research
Published: May 27, 2025
A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study).
Journal: Future oncology (London, England)
Published: May 20, 2025
EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 12, 2025
Last Updated: 09/26/2026